The fear: “Won’t ketamine break my sobriety?”

It is the first question almost everyone in recovery asks us, and it is the right question to ask. If you have spent years rebuilding a life around abstinence, the idea of an IV drip that produces a dissociative experience is going to set off every internal alarm you own. That instinct is healthy. We would be more concerned about the patient who shrugged it off.

Here is the honest framing. Ketamine is a Schedule III controlled substance with documented abuse potential. Recreational ketamine use is a real public-health issue, and chronic non-medical use carries significant risks to the bladder, the cognitive system, and the wallet. None of that goes away because we put it in a clinic. What does change, dramatically, is the dose, the setting, the supervision, the intent, and what happens before and after. Those variables are not cosmetic. In the addiction-medicine literature, they are most of what separates a therapeutic encounter from a harmful one.

Ketamine is FDA-approved as an anesthetic; its use for depression, PTSD, anxiety, and pain is off-label, and its use as part of a structured addiction protocol is also off-label and investigational. We say that out loud because anyone selling you a different story is selling you something. What follows is the actual evidence and how we think about it when someone in recovery asks for a consultation.

What Krupitsky’s studies actually found

Most of what we know about ketamine and abstinence comes from a Russian psychiatrist named Evgeny Krupitsky and his collaborators, who ran a series of careful trials between the late 1980s and the late 2000s. Their work is the foundation of every modern ketamine-assisted addiction protocol that exists.

A 2002 study by Krupitsky and colleagues, published in the Journal of Substance Abuse Treatment, randomized 70 detoxified heroin-dependent patients to receive either a high, psychedelic dose of ketamine paired with structured psychotherapy or a low, sub-psychedelic dose paired with the same psychotherapy. At the two-year follow-up, the high-dose group showed significantly greater abstinence, lower craving scores, and better mood than the active control group. The conclusion was not that ketamine prevented relapse mechanically, but that the combination of a dose strong enough to produce a transformative experience plus structured psychotherapy to make sense of it produced durable change.

A follow-up 2007 trial in the Journal of Psychoactive Drugs compared a single session of ketamine-assisted psychotherapy against three sessions in heroin-dependent patients. At one-year follow-up, 50% of the multi-session group remained abstinent versus 22% of the single-session group. That dose-response relationship is one of the more striking findings in the addiction literature, and it is part of why modern ketamine protocols rarely lean on a single infusion.

A review published in Neuropharmacology in 2018 by Jones and colleagues synthesized the broader evidence base on ketamine for addiction. The authors concluded that supportive evidence exists for ketamine-assisted treatment of alcohol and heroin dependence, and that the proposed mechanisms include increased neuroplasticity, glutamate modulation, and a motivational shift driven by the subjective experience itself. The review also cautioned that more rigorous, large-scale randomized trials are needed before ketamine-assisted addiction treatment can become a standard of care.

The signal from this body of work is consistent: in supervised, integrated settings, ketamine does not appear to drive relapse. In several trials, it appears to reduce it. That is the opposite of what most people in recovery initially fear.

The ASAM definition: addiction is a pattern, not a molecule

The American Society of Addiction Medicine defines addiction as “a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.” That definition is doing real work, and it is worth reading slowly.

Notice what is in the definition: pattern, compulsion, harm. Notice what is not in the definition: the molecule itself. Exposure to a controlled substance in a supervised medical setting, with a therapeutic intent and no pattern of compulsive use, does not meet the ASAM definition of addiction or relapse. This is the same logic by which a recovering alcoholic can receive midazolam during a colonoscopy, or fentanyl during a surgery, or an opioid for a fractured ankle, without it constituting a relapse.

That said, the addiction-medicine field is not unanimous on ketamine specifically. Some clinicians argue that the dissociative subjective effect is too close to the experience patients with substance use disorders are trying to leave behind, and that any psychedelic-adjacent treatment carries elevated risk of triggering compulsive use. Others, including the Krupitsky tradition, argue that the subjective experience is precisely what makes the treatment effective, and that the supervised setting is what keeps it safe. Both views are represented in the current ASAM literature, and the debate is genuine. Anyone who tells you the question is settled is overreaching.

Set, setting, and supervision: why clinical does not equal recreational

The classical psychedelic literature talks about “set and setting” for a reason. The same molecule, given in different contexts, produces different psychological outcomes and different addiction trajectories. That is not a hand-wave; it is a finding repeated across decades of research.

A clinical IV ketamine infusion at our practice differs from recreational use along almost every variable that matters:

The point is not that clinical ketamine is risk-free. No medication is. The point is that the variables driving addiction risk in the recreational context are systematically different in the clinical context, and the addiction-medicine evidence reflects that difference.

Talking to your sponsor, therapist, and recovery community

Recovery operates on transparency. The single most reliable predictor of trouble in our experience is a patient who is hiding the treatment from their sponsor or their group. Concealment corrodes the relationships that hold sobriety together, and it tends to escalate. We would rather you decided not to pursue ketamine than pursue it in secret.

Practical guidance, drawn from patients who have navigated this well:

Programs that have rejected vs. accepted medical ketamine

Recovery is not a monolith. Different programs and traditions have taken different positions on ketamine, and you deserve to know where the program you are in tends to land.

Alcoholics Anonymous and Narcotics Anonymous, at the national level, do not take a position on specific medications. AA’s pamphlet The AA Member, Medications and Other Drugs is explicit that decisions about prescribed medication are between the member and their physician, and that no AA member should play doctor. Individual sponsors and groups vary, sometimes considerably. Some sponsors are warm to medically-supervised psychiatric treatment, including ketamine. Others see any psychoactive substance as a bright line. Knowing which you have is part of doing this responsibly.

SMART Recovery and Refuge Recovery tend to be more openly accepting of medication-assisted approaches and ketamine specifically, often because their frameworks lean more directly on cognitive-behavioral and Buddhist-psychological models rather than abstinence theology. Faith-based recovery programs vary widely. Some are aligned with mainstream addiction medicine; others maintain a stricter abstinence definition that may include any controlled substance.

None of these positions makes one program right and another wrong. They reflect different theories of how recovery works. What matters for you is being honest about which framework you have signed onto and how that framework would view a clinical ketamine course.

Our protocol: integration support, transparency, no take-home

At Music City Ketamine we treat depression, PTSD, anxiety, OCD, bipolar depression, and chronic pain. We are not running an addiction-specific program, and we do not market ketamine as an addiction treatment. Many of our patients, however, are simply in long-term recovery and seeking treatment for a co-occurring condition. For those patients, our approach has a few non-negotiables.

We screen carefully. During your consultation we will ask about your recovery history, your current support structure, your medications including medication interactions with anything you are currently taking, and what your sponsor and therapist think. We are not gatekeeping for its own sake. We are trying to make sure the treatment fits the life. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring, the same standard described in our safety overview and is ketamine therapy safe writeup.

We do not dispense take-home ketamine. We coordinate with your prescribing team, your therapist, and (with your permission) your sponsor. We treat people in active recovery from alcohol use disorder, opioid use disorder, and stimulant use disorder, including patients on Suboxone, methadone, and naltrexone, but we do so collaboratively with their existing prescriber. If you are within the first six months of sustained recovery, we will usually want a longer conversation with your treatment team before proceeding.

There is also the cost question. Insurance does not generally cover off-label ketamine. Sessions at our clinic are $475 each, and we are transparent about that from the first phone call. If ketamine for addiction recovery is what you came looking for, the honest answer is that the evidence is supportive but not yet a standard of care, and our clinic treats co-occurring conditions rather than addiction itself. We will tell you that on the consultation, not after the deposit.

If you are in recovery and considering this, the step we would suggest is a conversation, not a commitment. Bring your sponsor. Bring your therapist. Bring your skepticism. We would rather coordinate openly than work around the people who keep you sober.